Understanding Paraneoplastic Polyneuropathy
At a Glance
Paraneoplastic polyneuropathy is not cancer spreading to the nerves. It occurs when the immune system mistakenly attacks nerves in response to a tumor, causing numbness, pain, balance problems, dizziness, constipation, or unusual sweating. Treating the cancer may stabilize or improve nerve symptoms.
If you are reading this, you may have spent weeks or even months visiting different doctors, trying to explain strange sensations in your hands or feet, only to be told that the cause is actually related to a cancer you didn’t know you had. This experience—where the body’s alarm system for a tumor is a neurological symptom—can be profoundly disorienting.
Paraneoplastic polyneuropathy (PPN) is a rare condition where your immune system, while trying to fight off a cancer, cross-reacts with your peripheral nerves [1]. It is important to understand that this is not the cancer “spreading” to your nerves; rather, it is a case of “mistaken identity” by your own defenses.
A Misdirected Immune Response
To understand PPN, it helps to think of your immune system as a defense team. When a tumor develops, it sometimes produces proteins that are also naturally shared with the nervous system. Your immune system recognizes these proteins as “foreign” and creates onconeural antibodies—biomarkers designed to target the tumor [2].
However, because these proteins also exist on your healthy nerve cells, the immune system may accidentally target your nerves as well [2]. This “cross-reactivity” causes the inflammation and damage that leads to your symptoms.
- It is not a metastasis: The cancer cells are not physically invading the nerves [3].
- Other Causes Must Be Evaluated: While this mechanism is suspected, doctors must still carefully evaluate for other coexisting explanations, such as diabetes, nutritional deficiencies, or medication toxicity [1].
- It is an immune signal: In many cases, these nerve symptoms act as an early warning sign, appearing months or even years before the cancer is found on a scan [4].
Distinguishing PPN from Other Nerve Issues
Because many people with cancer also receive chemotherapy, it can be difficult to tell PPN apart from chemotherapy-induced peripheral neuropathy (CIPN). Your doctors use several clues to make this distinction, though these are general tendencies and both conditions can coexist:
| Feature | Tendencies in Paraneoplastic (PPN) | Tendencies in Chemotherapy-Induced (CIPN) |
|---|---|---|
| Timing | Often starts before any treatment begins, though can begin later [4]. | Starts during or shortly after chemo cycles [5]. |
| Primary Symptoms | Often involves “sensory ataxia” (loss of balance) or severe pain [1]. | Usually a “glove-and-stocking” numbness in hands and feet [6]. |
| Antibodies | Specific onconeural antibodies (like Anti-Hu or CRMP5) are often present in the blood [2]. | No specific antibodies are associated with this [7]. |
| Progression | Can progress rapidly over weeks or months [1]. | Typically develops gradually as chemo doses add up [5]. |
The “Diagnostic Odyssey” and Emotional Impact
The path to a PPN diagnosis is rarely a straight line. Many patients go through a “diagnostic odyssey”—a long period of testing for diabetes, vitamin deficiencies, or pinched nerves—before the true cause is found [3].
It is common to feel a sense of “emotional whiplash” during this process. You may have started by seeking help for a balance problem or tingling in your fingers, only to have the conversation suddenly shift to a search for a hidden tumor. Validating this shock is a key part of your care; the neurological symptoms are not “all in your head,” and the anxiety of searching for an unseen cancer is a heavy burden [8].
What Standard Care Looks Like
Once PPN is suspected, your medical team will likely take a “dual-track” approach:
- Finding and Treating the Tumor: The most effective way to stop the immune attack on your nerves is to address the “trigger”—the cancer itself [9]. In many cases, treating the tumor can stabilize or even improve nerve symptoms [10].
- Modulating the Immune System: Doctors may use treatments to “quiet” the overactive immune response. This can include IVIG (intravenous immunoglobulin), plasmapheresis (plasma exchange), or steroids [11][12].
- Managing Symptoms: This includes medications for nerve pain, such as gabapentin or certain antidepressants, and physical therapy to help with balance and mobility [13][14].
Because this condition is rare, your care often requires a “multidisciplinary team”—a group of specialists including neurologists, oncologists, and sometimes palliative care experts (who provide symptom management and quality-of-life support during active treatment) who work together to manage both the cancer and the nerve damage [15][8].
Common questions in this guide
Is paraneoplastic polyneuropathy caused by cancer spreading to the nerves?
What symptoms can paraneoplastic polyneuropathy cause?
How can doctors tell PPN from chemotherapy-related neuropathy?
What do onconeural antibody results mean in PPN?
Can treating the underlying cancer improve the nerve symptoms?
Which specialists treat paraneoplastic polyneuropathy?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Other causes
Could other causes, such as diabetes or nutritional deficiencies, be checked for my nerve symptoms?
Treatment options
Which treatments could be considered to quiet the immune response in my case?
Cancer and nerves
Could treating the cancer help stabilize or improve my nerve symptoms?
Get notified when new evidence is published on paraneoplastic polyneuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria.
Zoccarato M, Grisold W, Grisold A, et al.
Frontiers in neurology 2021; (12()):706169 doi:10.3389/fneur.2021.706169.
PMID: 34659082 - 2
Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders.
Shelly S, Dubey D, Mills JR, Klein CJ
Handbook of clinical neurology 2024; (200()):239-273 doi:10.1016/B978-0-12-823912-4.00020-7.
PMID: 38494281 - 3
Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.
Chiang JCB, Arnold R, Dhanapalaratnam R, et al.
Pharmaceuticals (Basel, Switzerland) 2022; (15(5)) doi:10.3390/ph15050607.
PMID: 35631433 - 4
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.
Villagrán-García M, Farina A, Muñiz-Castrillo S, et al.
Brain communications 2023; (5(5)):fcad247 doi:10.1093/braincomms/fcad247.
PMID: 37794924 - 5
Chronic Oxaliplatin Treatment Induces CIPN in Mice via Activation of the TXNIP Pathway.
Du J, Sudlow LC, Shahverdi K, et al.
Molecular neurobiology 2025; (63(1)):92 doi:10.1007/s12035-025-05463-7.
PMID: 41261287 - 6
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.
Starobova H, Vetter I
Frontiers in molecular neuroscience 2017; (10()):174 doi:10.3389/fnmol.2017.00174.
PMID: 28620280 - 7
Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.
Myftiu B, Hundozi Z, Sermaxhaj F, et al.
Medical science monitor : international medical journal of experimental and clinical research 2022; (28()):e937856 doi:10.12659/MSM.937856.
PMID: 36042691 - 8
Paraneoplastic Syndromes Associated with Gynecologic Neoplasms: Experience from a Tertiary Care Center in South India.
Sudhakaran S, Acharya G, Kulkarni KA, et al.
South Asian journal of cancer 2024; (13(3)):185-190 doi:10.1055/s-0043-1772223.
PMID: 39410983 - 9
A case of IVIg responsive paraneoplastic SOX1 peripheral neuropathy in a male with breast carcinoma.
Beer R, O'Gorman C, Horwood K, Blum S
Journal of neuroimmunology 2021; (352()):577492 doi:10.1016/j.jneuroim.2021.577492.
PMID: 33508769 - 10
Persistent pain and numbness in the extremities of an adult due to paraneoplastic peripheral neuropathy caused by olfactory neuroblastoma: A case report.
Liang W, Wang Y, Sun W, et al.
Frontiers in neurology 2022; (13()):1002076 doi:10.3389/fneur.2022.1002076.
PMID: 36698887 - 11
Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report.
Sreter KB, Barisic B, Barisic Kutija M, et al.
Molecular and clinical oncology 2017; (6(6)):921-924 doi:10.3892/mco.2017.1248.
PMID: 28588791 - 12
Paraneoplastic sensorimotor neuropathy and ventral cauda equina nerve root enhancement as initial presentation of small cell lung carcinoma: a case study.
Alsaeed M, Lim CAR, Plecash A, Chen T
BMC neurology 2021; (21(1)):374 doi:10.1186/s12883-021-02404-4.
PMID: 34579672 - 13
Distal Symmetric Polyneuropathy: A Review.
Callaghan BC, Price RS, Feldman EL
JAMA 2015; (314(20)):2172-81 doi:10.1001/jama.2015.13611.
PMID: 26599185 - 14
Paraneoplastic sensorimotor polyneuropathy in prostatic adenocarcinoma: A case report.
Choi JK, Kim WJ, Jeon JY
Medicine 2018; (97(15)):e0030 doi:10.1097/MD.0000000000010030.
PMID: 29642138 - 15
[Paraneoplastic cerebellar degeneration (PCD) - an interdisciplinary challenge in neurology, oncology and palliative care].
Burger S, Lorenzl S
Wiener medizinische Wochenschrift (1946) 2018; (168(7-8)):193-198 doi:10.1007/s10354-018-0624-4.
PMID: 29411193
This page explains how a cancer-related immune response can affect the peripheral nerves for educational purposes only. It does not replace medical advice from your neurologist, oncologist, or other healthcare professional about your specific symptoms and care.